243 related articles for article (PubMed ID: 30300141)
1. Bone marrow transplantation generates T cell-dependent control of myeloma in mice.
Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR
J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141
[TBL] [Abstract][Full Text] [Related]
2. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
3. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
4. Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Guillerey C; Ferrari de Andrade L; Vuckovic S; Miles K; Ngiow SF; Yong MC; Teng MW; Colonna M; Ritchie DS; Chesi M; Bergsagel PL; Hill GR; Smyth MJ; Martinet L
J Clin Invest; 2015 May; 125(5):2077-89. PubMed ID: 25893601
[TBL] [Abstract][Full Text] [Related]
5. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
6. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.
Minnie SA; Kuns RD; Gartlan KH; Zhang P; Wilkinson AN; Samson L; Guillerey C; Engwerda C; MacDonald KPA; Smyth MJ; Markey KA; Vuckovic S; Hill GR
Blood; 2018 Oct; 132(16):1675-1688. PubMed ID: 30154111
[TBL] [Abstract][Full Text] [Related]
7. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
8. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Xu W; Jones M; Liu B; Zhu X; Johnson CB; Edwards AC; Kong L; Jeng EK; Han K; Marcus WD; Rubinstein MP; Rhode PR; Wong HC
Cancer Res; 2013 May; 73(10):3075-86. PubMed ID: 23644531
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
11. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
[TBL] [Abstract][Full Text] [Related]
13. CBLB Constrains Inactivated Vaccine-Induced CD8
Nanjappa SG; Mudalagiriyappa S; Fites JS; Suresh M; Klein BS
J Immunol; 2018 Sep; 201(6):1717-1726. PubMed ID: 30054317
[TBL] [Abstract][Full Text] [Related]
14. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
Qian J; Hong S; Wang S; Zhang L; Sun L; Wang M; Yang J; Kwak LW; Hou J; Yi Q
Blood; 2009 Oct; 114(18):3880-9. PubMed ID: 19654406
[TBL] [Abstract][Full Text] [Related]
15. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
16. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.
Kawano Y; Zavidij O; Park J; Moschetta M; Kokubun K; Mouhieddine TH; Manier S; Mishima Y; Murakami N; Bustoros M; Pistofidis RS; Reidy M; Shen YJ; Rahmat M; Lukyanchykov P; Karreci ES; Tsukamoto S; Shi J; Takagi S; Huynh D; Sacco A; Tai YT; Chesi M; Bergsagel PL; Roccaro AM; Azzi J; Ghobrial IM
J Clin Invest; 2018 Jun; 128(6):2487-2499. PubMed ID: 29558366
[TBL] [Abstract][Full Text] [Related]
17. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
18. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Cui Y; Kelleher E; Straley E; Fuchs E; Gorski K; Levitsky H; Borrello I; Civin CI; Schoenberger SP; Cheng L; Pardoll DM; Whartenby KA
Nat Med; 2003 Jul; 9(7):952-8. PubMed ID: 12778137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
